Article and Video CATEGORIES

Cancer Journey

Search By

Assistant Professor of Medicine, Hospital of the University of Pennsylvania, and the Veteran’s Administration Medical Center

ASCO/ESMO 2020 Debio 1143/ Xevinapant Study Update
dbrock
Debio/ Xevinapant Study Update
What Have We Learned About Debio 1143 (Xevinapant) in Combination with Chemoradiation Therapy for Patients With HNSCC
Author
Joshua Bauml, MD, Advisory Board Member, GRACE Faculty
Image
We are pleased to present this newest video series of updates from ASCO and ESMO 2020, with discussions on updates to head and neck cancer treatments and trials.

Dr. Joshua Bauml, Assistant Professor of Medicine at the Hospital of the University of Pennsylvania and Dr. Jared Weiss, Associate Professor of Medicine at UNC Chapel Hill and Vice President of the Board of GRACE chaired this program.

Drs. Bauml and Weiss spoke with Dr. Kathryn Gold, Medical Oncologist and Associate Professor of Medicine at the University of California San Diego and Dr. Ranee Mehra, Professor of Medical Oncology at the University of Maryland, on the newest updates to 2020 trials and studies presented at ASCO and ESMO this year.

 

For this discussion, Drs. Bauml, Weiss, Gold and Mehra discuss what we have learned about Debio 1143 (Xevinapant) in combination with chemoradiation therapy for patients With HNSCC.

We thank Varian for their support of this program!

 

To join the conversation, visit https://cancergrace.org/forum.

Video Language

Next Previous link

Previous PostNext Post

Related Content

Online Community

Hi app.92,  Welcome to Grace.  I'm sorry this is late getting to you. And more sorry your mum is going through this.  It's possible this isn't a pancoast tumor even though...

A Brief Tornado.  I love the analogy Dr. Antonoff gave us to describe her presentation.  I felt it earlier too and am looking forward to going back for deeper dive.

Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".

While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".  

I hope any...

My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.

Here's the webinar on YouTube.  It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics

An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:

  1. The antibody, which serves as the “horse,” specifically targets a protein found on cancer...

Recent Comments

JOIN THE CONVERSATION
Hi app.92,  Welcome to Grace…
By JanineT GRACE … on
Webinar OnDemand
By JanineT GRACE … on
My understanding of ADCs is…
By JanineT GRACE … on
Right patient, right time,…
By JanineT GRACE … on